Patents
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2013
11/21/2013US20130309307 Bilayer Pharmaceutical Tablet Comprising Telmisartan and a Diuretic and Preparation Thereof
11/21/2013US20130309303 Opiod Agonist Formulations with Releasable And Sequestered Antagonist
11/21/2013US20130309301 Salts of potassium atp channel openers and uses thereof
11/21/2013US20130309292 Tobacco Alkaloid Releasing Chewing Gum
11/21/2013US20130309290 Gamma-tocopherol therapy for restenosis prevention
11/21/2013US20130309268 Compositions including transfer factor derived from eggs
11/21/2013US20130309247 Dimeric iap inhibitors
11/21/2013US20130309232 Vascular endothelial growth factor 2
11/21/2013US20130309229 Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases
11/21/2013US20130309228 Pyrimidinediamine kinase inhibitors
11/21/2013US20130309219 Treatment and Prevention of Bacterial Vaginosis and Gardnerella Vaginalis Infections
11/21/2013US20130309216 Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose
11/21/2013US20130309202 Methods for Improving Liver Function
11/21/2013US20130309200 Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as jak inhibitors
11/21/2013US20130309199 Novel Treatment of Multiple Sclerosis (MS)
11/21/2013US20130309197 Inhibitors of cytochrome p450
11/21/2013US20130309195 Antiviral compounds
11/20/2013EP2663672A1 Prognostic signature for oral squamous cell carcinoma
11/20/2013EP2663560A1 Crystalline oxazine derivative and its use as bace inhibitor
11/20/2013EP2663335A1 A composition for the regeneration of atrophic tissues
11/20/2013EP2663305A1 Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
11/20/2013EP2663303A1 Anticancer therapy with dual aurora kinase / mek inhibitors
11/20/2013EP2663299A1 Melatonin and an antimicrobial or antibacterial agent for the treatment of acne
11/20/2013EP2663189A1 Combination
11/20/2013EP2441760B1 Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
11/20/2013EP2340022B1 Combination therapy for tuberculosis
11/20/2013EP2272869B1 Angiopoietin-2 specific binding agents
11/20/2013EP2251014B1 Combinations of an anti-cancer agent and a cholestanol derivative
11/20/2013EP2203478B1 Compositions and methods for use of antibodies against sclerostin
11/20/2013EP2143429B1 Use of cilastatin to reduce the nephrotoxicity of different compounds
11/20/2013EP2075334B1 EG-VEGF nucleic acids and polypeptides and methods of use
11/20/2013EP2040735B1 Isolated cationic fraction for treating a microbial infection
11/20/2013EP1847244B1 Metabolic syndrome-improving agent and medicine, supplement, functional food and food additive containing the same
11/20/2013EP1690545B1 Preparation of Product R and product so obtained
11/20/2013EP1613628B1 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof
11/20/2013CN103402542A Medicinal agent for inhibiting metastasis of malignant tumor
11/20/2013CN103402527A Compositions and methods for cell transplantation
11/20/2013CN103402514A Combinations of serotonin receptor agonists for treatment of movement disorders
11/20/2013CN103402507A Arylsulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders
11/20/2013CN103402506A Combination for treatment of diabetes mellitus
11/20/2013CN103402499A Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
11/20/2013CN103396491A Monoclonal antibodies against human anti-mullerian hormone type II receptor (AMHR-II), and manufacturing method thereof and application
11/20/2013CN103394091A Analgesic anti-inflammatory preparation for external application
11/20/2013CN103394090A Opioids for treatment of restless leg syndrome (RLS)
11/20/2013CN103394089A Application of DPP-IV inhibitor in type 2 diabetes
11/20/2013CN103394088A Method of selecting antioxidants for use in topically applied compositions
11/20/2013CN103394087A Dosage form time-lagged of drugs for therapy of insomnia
11/20/2013CN103394078A Self-pressurized multi-target collaborative hemostasis degradable hemostatic preparation for injury first aid
11/20/2013CN103393695A Methods and compositions for treatment and management of multiple myeloma
11/20/2013CN103393681A Methodand composition for treatment and management of multiple myeloma
11/20/2013CN103393672A Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
11/20/2013CN102743754B Esophagus gastrointestinal mucosa protective adhesive preparation and application thereof
11/20/2013CN102552909B Composition for treating proteinuria and preparation method for composition
11/20/2013CN102448450B Compositions comprising trans-tert-butyl cyclohexanol as skin irritation-reducing agent
11/20/2013CN102215870B Diagnosis method and therapeutic method for cancer
11/20/2013CN101703761B Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity
11/19/2013US8586633 Ophthalmologic irrigation solutions and method
11/19/2013US8586629 Composition for the treatment of oxidative stress
11/19/2013US8586555 Immunomodulatory compositions, formulations, and methods for use thereof
11/19/2013US8586544 Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component
11/19/2013US8586543 IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors
11/19/2013US8586524 Modulators of pharmacological agents
11/19/2013US8586317 Methods of diagnosing hypophosphatemic disorders
11/19/2013US8586088 Tamper-resistant oral opioid agonist formulations
11/19/2013US8586066 Topical antifungal composition
11/19/2013US8586008 Pharmaceutical foam
11/19/2013CA2590211C Oral treatment compositions containing an anti-adhesion agent, antibacterial agent and incompatible compound
11/19/2013CA2515929C Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
11/19/2013CA2496213C Metalloprotease activation of myostatin, and methods of modulating myostatin activity
11/19/2013CA2447139C Specific binding proteins and uses thereof
11/19/2013CA2425842C Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia
11/19/2013CA2329757C Use of .alpha.1.beta.1 integrin receptor inhibitors and tgf-.beta.1 inhibitors in the treatment of kidney disease
11/14/2013WO2013169218A1 Pharmaceutical compositions of s-etodolac
11/14/2013WO2013168826A1 Method for screening for prophylactic or therapeutic agent for diseases or disorders associated with inflammation-related feedback loop
11/14/2013WO2013168315A1 Therapeutic or prophylactic agent for dementia and behavioral and psychological symptoms
11/14/2013WO2013167906A1 Treatment of respiratory depression
11/14/2013WO2013167743A1 Use of compounds for the treatment of pain
11/14/2013WO2013167554A1 Pharmaceutical combinations for the treatment of metabolic disorders
11/14/2013WO2013167475A1 Anabolic compounds for treating and preventing bone loss diseases
11/14/2013US20130303976 Methods and Systems for Conditioning in Surgery
11/14/2013US20130303620 Injectable Capsaicin
11/14/2013US20130303615 Antimicrobial compositions and methods
11/14/2013US20130303612 Solid dosage form comprising a fibrate
11/14/2013US20130303585 Small molecule rnase inhibitors and methods of use
11/14/2013US20130303583 Methods of treating headaches using 5-ht agonists in combination with long-acting nsaids
11/14/2013US20130303578 Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
11/14/2013US20130303570 Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
11/14/2013US20130303559 Benzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases
11/14/2013US20130303554 Use of a dpp-4 inhibitor in sirs and/or sepsis
11/14/2013US20130303552 Novel inhibitors of secretion of hepatitis b virus antigens
11/14/2013US20130303551 Pyrimidinone derivatives as fatty acid synthase inhibitors
11/14/2013US20130303548 Indication for use of niacin (nicotinic acid) for treatment, prevention and reversal of fatty liver disease
11/14/2013US20130303542 Substituted pyrazinamide compounds for inflammation and immune-related uses
11/14/2013US20130303539 Compounds with trpv4 activity, compositions and associated methods thereof
11/14/2013US20130303538 4-Tolyl-ethynyl-octahydro-indole-1-ester derivatives
11/14/2013US20130303533 Azolopyridine and azolopyrimidine compounds and methods of use thereof
11/14/2013US20130303529 Fused heterocyclic derivatives and methods of use
11/14/2013US20130303524 Carbazole-Containing Sulfonamides as Cryptochrome Modulators
11/14/2013US20130303523 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
11/14/2013US20130303517 Quinoxalines and aza-quinoxalines as crth2 receptor modulators
1 ... 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 ... 1151